Manini MA, et al. - This study examined the efficacy of entecavir (ETV) or tenofovir (TDF ) monotherapy for the prevention of HBV recurrence following liver transplantation (LT) between 01/2010 and 03/2012. Group A comprised 69 HBV monoinfected patients and Group B 8 HBV/HDV co-infected patients. Undetectable HBV-DNA levels and stable graft function during 30 months of additional follow-up were exhibited by the subjects. Findings disclosed that HBIG could be safely discontinued in HBsAgpositive LT recipients and replaced by ETV or TDF monotherapy.